NCT00542958View on ClinicalTrials.gov

Study of NK012 in Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2011

Conditions
Cancer
Interventions
DRUG

NK012

9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion

Trial Locations (1)

37203

Sarah Cannon Research Institute, Nashville

Sponsors
All Listed Sponsors
lead

Nippon Kayaku Co., Ltd.

INDUSTRY

NCT00542958 - Study of NK012 in Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter